4 recruiting, 3 unknown, 2 active not recruiting, 1 completed. 11 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 4, Unknown 3, Active not recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Radiation Therapy: new trials by email Literature Review of Radiation Therapy trials Research Report on Radiation Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz - Non Small Cell Lung Cancer, Cardiotoxicity | Phase 2 | Recruiting | Indiana University | 10 | 2026-09-01 | 2026-09-15 |
| GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries Volume Modulated Arc Therapy (VMAT), Intensity Modulated Proton Therapy (IMPT) - Gynaecologic Cancer, Cervical Cancer | Phase 2 | Recruiting | University of Maryland, Baltimore | 116 | 2026-03-25 | 2026-08-10 |
| Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advanced Colon Cancer: A Prospective, Single-Arm, Phase II Trial Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor - Colon Cancer, Neoadjuvant Therapies | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 38 | 2025-11-26 | 2025-12-26 |
| Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy Elacestrant, PULSAR - Breast Cancer Patients, Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria Careggi | 21 | 2025-09-01 | 2025-06-05 |
| Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial Pembrolizumab, Eftilagimod alfa - Neoadjuvant, Immunotherapy | Phase 2 | Active not recruiting | Maria Sklodowska-Curie National Research Institute of Oncology | 40 | 2023-07-17 | 2025-12-08 |
| Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma Camrelizumab, Paclitaxel, Cisplatin - Chemotherapy, Radiation Therapy | Phase 2 | Unknown | Fujian Medical University Union Hospital | 40 | 2023-05-25 | 2023-04-20 |
| Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy Toripalimab, Tegafur, IMRT - Esophageal Cancer, Radiation Therapy | Phase 2 / Phase 3 | Unknown | Taizhou Hospital | 60 | 2022-07-01 | 2023-04-18 |
| Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) Paclitaxel, Carboplatin, Radiotherapy - Esophagus Cancer, Esophageal Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Fudan University | 70 | 2020-05-30 | 2023-08-03 |
| SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC Stereotactic Ablative Body Radiotherapy (SABR), TORIPALIMAB INJECTION(JS001 ), Axitinib (VEGF-TKI) - Radiation Therapy, Targeted Therapy | Phase 2 | Recruiting | Peking University First Hospital | 30 | 2019-01-01 | 2025-03-21 |
| Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer Radiation therapy - Breast Cancer, Radiation Therapy | Phase 2 | Unknown | Instituto do Cancer do Estado de São Paulo | 1 | 2017-06-01 | 2017-07-11 |
| Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma mid-position radiation strategy, ITV - Non-small Cell Lung Cancer, Radiation Therapy | Phase 2 | Completed | Centre Leon Berard | 54 | 2012-09-12 | 2021-02-05 |
Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Breast Neoplasms (1) · Cardiotoxicity (1) · Colonic Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Radiation Injuries (1) · Sarcoma (1) · Uterine Cervical Neoplasms (1)
Neoplasms (8) · Neoplasms by Site (7) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Esophageal Diseases (2) · Head and Neck Neoplasms (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms by Histologic Type (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2)
Radiotherapy (3) · Paclitaxel (2) · Axitinib (1) · Carboplatin (1) · Cisplatin (1) · DEAE-Dextran (1) · DMAC2L protein, human (1) · Drug Therapy (1) · Immune Checkpoint Inhibitors (1) · Injections (1) · Radiation (1) · Radiotherapy, Intensity-Modulated (1) · S 1 (combination) (1) · Tegafur (1) · camrelizumab (1)
Azienda Ospedaliero-Universitaria Careggi (1) · Centre Leon Berard (1) · Fudan University (1) · Fujian Medical University Union Hospital (1) · Indiana University (1) · Instituto do Cancer do Estado de São Paulo (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Peking University First Hospital (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Taizhou Hospital (1) · University of Maryland, Baltimore (1)
China (5) · United States (2) · Brazil (1) · France (1) · Italy (1) · Poland (1)
Chun Chen, Prof (1) · Elizabeth Nichols, MD (1) · Jordan Holmes, MD (1) · Katarzyna Kozak (1) · Kuaile Zhao (1)
PMID 38418234, PMID 40503038, PMID 41531940
2025 (1)